These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8683698)

  • 1. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Klein EA
    J Urol; 1996 Aug; 156(2 Pt 1):443-4. PubMed ID: 8683698
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    J Urol; 1997 Apr; 157(4):1371. PubMed ID: 9120953
    [No Abstract]   [Full Text] [Related]  

  • 3. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
    Roberts RO; Bergstralh EJ; Peterson NR; Bostwick DG; Lieber MM; Jacobsen SJ
    J Urol; 2000 May; 163(5):1471-5. PubMed ID: 10751860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115).
    Papatsoris A; Albanis S; Deliveliotis C
    Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
    Finney Rutten LJ
    Eur Urol; 2008 Jun; 53(6):1193. PubMed ID: 17709172
    [No Abstract]   [Full Text] [Related]  

  • 7. Biopsies for "normal" PSA? Certain relatively young, healthy men with PSA levels below 4 should consider having a biopsy.
    Gerber GS
    Health News; 2004 Jul; 10(7):4-5. PubMed ID: 15239153
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.
    Lazzeri M; Briganti A; Scattoni V; Lughezzani G; Larcher A; Gadda GM; Lista G; Cestari A; Buffi N; Bini V; Freschi M; Rigatti P; Montorsi F; Guazzoni G
    J Urol; 2012 Oct; 188(4):1137-43. PubMed ID: 22901578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Mishra VC; Motiwala HG
    BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181
    [No Abstract]   [Full Text] [Related]  

  • 10. Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.
    Helfand BT; Loeb S; Hu Q; Cooper PR; Roehl KA; McGuire BB; Baumann NA; Catalona WJ
    J Urol; 2013 May; 189(5):1697-701. PubMed ID: 23246478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.
    Stamey TA
    BJU Int; 2004 Nov; 94(7):963-4. PubMed ID: 15541106
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Shimbo M
    Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131
    [No Abstract]   [Full Text] [Related]  

  • 13. The prostate biopsy.
    Harv Mens Health Watch; 2003 Jul; 7(12):4-7. PubMed ID: 12888462
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining prostate cancer risk before prostate biopsy.
    Pal RP; Maitra NU; Mellon JK; Khan MA
    Urol Oncol; 2013 Nov; 31(8):1408-18. PubMed ID: 22795499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment from Dr Urakami to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Urakami S
    Int J Urol; 2014 Oct; 21(10):990-1. PubMed ID: 24909066
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment from Dr Simonato and Dr Romagnoli to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Simonato A; Romagnoli A
    Int J Urol; 2014 Oct; 21(10):991. PubMed ID: 24931339
    [No Abstract]   [Full Text] [Related]  

  • 17. [Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study].
    Reis LO; Zani EL; Alonso JC; Simões FA; Rejowski RF; Ferreira U
    Actas Urol Esp; 2011 Jan; 35(1):10-4. PubMed ID: 21256389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of percent free prostate-specific antigen in repeat prostate biopsy.
    Lee BH; Hernandez AV; Zaytoun O; Berglund RK; Gong MC; Jones JS
    Urology; 2011 Aug; 78(2):386-91. PubMed ID: 21683989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
    Keetch DW; Catalona WJ
    J Urol; 1995 Nov; 154(5):1795-7. PubMed ID: 7563349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times.
    Stamey TA
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):967-8; discussion 972. PubMed ID: 7591913
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.